Search Results - "Mayur, Ramesh"

Reply to Fernandez Cruz, et al by Alangaden, George, Ramesh, Mayur S

Get full text

Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19 by Fadel, Raef, Morrison, Austin R, Vahia, Amit, Smith, Zachary R, Chaudhry, Zohra, Bhargava, Pallavi, Miller, Joseph, Kenney, Rachel M, Alangaden, George, Ramesh, Mayur S

“…Abstract Background There is no proven antiviral or immunomodulatory therapy for coronavirus disease 2019 (COVID-19). The disease progression associated with…”
Get full text

Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study by Orenstein, Robert, Dubberke, Erik, Hardi, Robert, Ray, Arnab, Mullane, Kathleen, Pardi, Darrell S., Ramesh, Mayur S.

“…Background. Managing recurrent Clostridium difficile infection (CDI) presents a significant challenge for clinicians and patients. Fecal microbiota…”
Get full text

Clinical characteristics and outcomes of COVID‐19 in solid organ transplant recipients: A cohort study by Chaudhry, Zohra S., Williams, Jonathan D., Vahia, Amit, Fadel, Raef, Parraga Acosta, Tommy, Prashar, Rohini, Shrivastava, Pritika, Khoury, Nadeen, Pinto Corrales, Julio, Williams, Celeste, Nagai, Shunji, Abouljoud, Marwan, Samaniego‐Picota, Milagros, Abreu‐Lanfranco, Odaliz, Busto, Ramon, Ramesh, Mayur S., Patel, Anita, Alangaden, George J.

“…Solid organ transplant recipients (SOTr) with coronavirus disease 2019 (COVID‐19) are expected to have poorer outcomes compared to nontransplant patients…”
Get full text

Response to “Is the outcome of SARS‐CoV‐2 infection in solid organ transplant recipients really similar to that of the general population?” by Alangaden, George J., Mayur, Ramesh S.

Get full text

SARS‐CoV‐2 neutralizing antibodies for COVID‐19: Outcomes for bamlanivimab versus bamlanivimab‐etesevimab combination in a racially diverse cohort of patients with significant comorbidities by Monday, Lea M., Brar, Indira, Alangaden, George, Ramesh, Mayur S.

“…What Is Known and Objective Anti‐spike monoclonal antibodies (MAB) including bamlanivimab (BAM) and bamlanivimab/etesevimab (BAM/E) have shown reduced…”
Get full text

Are Bacteria Infectious Pathogens in Hidradenitis Suppurativa? Debate at the Symposium for Hidradenitis Suppurativa Advances Meeting, November 2017 by Naik, Haley B., Nassif, Aude, Ramesh, Mayur S., Schultz, Gregory, Piguet, Vincent, Alavi, Afsaneh, Lowes, Michelle A.

“…In November 2017, a formal debate on the role of bacteria in the pathogenesis of hidradenitis suppurativa (HS) was held at the 2nd Symposium on Hidradenitis…”
Get full text

Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab by Morrison, Austin R., Johnson, Joseph M., Griebe, Kristin M., Jones, Mathew C., Stine, John J., Hencken, Laura N., To, Long, Bianchini, Monica L., Vahia, Amit T., Swiderek, Jennifer, Ramesh, Mayur S., Peters, Michael A., Smith, Zachary R.

“…Coronavirus disease 2019 (COVID-19) can progress to cytokine storm that is associated with organ dysfunction and death. The purpose of the present study is to…”
Get full text

Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease by Salgia, Reena, Ramesh, Mayur S., Alimirah, Maryam, Meighani, Alireza

“…Background. Fecal microbiota transplantation (FMT) is a well-established therapeutic option for patients with antibiotic resistant Clostridioides difficile…”
Get full text

A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response by Okhuysen, Pablo C, Ramesh, Mayur S, Louie, Thomas, Kiknadze, Nino, Torre-Cisneros, Julian, de Oliveira, Claudia Murta, Van Steenkiste, Christophe, Stychneuskaya, Alena, Garey, Kevin W, Garcia-Diaz, Julia, Li, Jianling, Duperchy, Esther, Chang, Betty Y, Sukbuntherng, Juthamas, Montoya, Jose G, Styles, Lori, Clow, Fong, James, Danelle, Dubberke, Erik R, Wilcox, Mark

“…Abstract Background Exposure to antibiotics predisposes to dysbiosis and Clostridioides difficile infection (CDI) that can be severe, recurrent (rCDI), and…”
Get full text

Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3 by Bhagwat, Sachin S, Hariharan, Periasamy, Joshi, Prashant R, Palwe, Snehal R, Shrivastava, Rahul, Patel, Mahesh V, Devanga Ragupathi, Naveen Kumar, Bakthavatchalam, Yamuna Devi, Ramesh, Mayur S, Soman, Rajeev, Veeraraghavan, Balaji

“…Recent reports reveal the emergence of Escherichia coli isolates harbouring a novel resistance mechanism based on four-amino-acid inserts in PBP3. These…”
Get full text

Characterization of BK Polyomaviruses from Kidney Transplant Recipients Suggests a Role for APOBEC3 in Driving In-Host Virus Evolution by Peretti, Alberto, Geoghegan, Eileen M., Pastrana, Diana V., Smola, Sigrun, Feld, Pascal, Sauter, Marlies, Lohse, Stefan, Ramesh, Mayur, Lim, Efrem S., Wang, David, Borgogna, Cinzia, FitzGerald, Peter C., Bliskovsky, Valery, Starrett, Gabriel J., Law, Emily K., Harris, Reuben S., Killian, J. Keith, Zhu, Jack, Pineda, Marbin, Meltzer, Paul S., Boldorini, Renzo, Gariglio, Marisa, Buck, Christopher B.

“…BK polyomavirus (BKV) frequently causes nephropathy (BKVN) in kidney transplant recipients (KTRs). BKV has also been implicated in the etiology of bladder and…”
Get full text

Ciprofloxacin versus levofloxacin prophylaxis in hematopoietic stem cell transplantation: A randomized trial by Farhan, Shatha, Mazur, Izabela, Hartzell, Susan, Xie, Peter, Neme, Klodiana, German, Angela, Mikulandric, Nancy, Patel, Kunj, Wu, Min, Kortam, Neda, Yaseen, Aseel, Sweidan, Aroob, Latack, Katie, Emole, Josephine, Peres, Edward, Abidi, Muneer H., Ramesh, Mayur

“…•No difference in bloodstream infections between ciprofloxacin and levofloxacin.•No difference in other secondary outcomes.•Pneumonia was more frequent in the…”
Get full text

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 by Arshad, Samia, Kilgore, Paul, Chaudhry, Zohra S., Jacobsen, Gordon, Wang, Dee Dee, Huitsing, Kylie, Brar, Indira, Alangaden, George J., Ramesh, Mayur S., McKinnon, John E., O’Neill, William, Zervos, Marcus, Nauriyal, Varidhi, Hamed, Asif Abdul, Nadeem, Owais, Swiderek, Jennifer, Godfrey, Amanda, Jennings, Jeffrey, Gardner-Gray, Jayna, Ackerman, Adam M., Lezotte, Jonathan, Ruhala, Joseph, Fadel, Raef, Vahia, Amit, Gudipati, Smitha, Parraga, Tommy, Shallal, Anita, Maki, Gina, Tariq, Zain, Suleyman, Geehan, Yared, Nicholas, Herc, Erica, Williams, Johnathan, Lanfranco, Odaliz Abreu, Bhargava, Pallavi, Reyes, Katherine

“…•As of May 27, 2020 there are over 1,678,843 confirmed cases of COVID-19 claiming more than 100,000 lives in the Unites States. Currently there is no known…”
Get full text

Ertapenem – a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa by Braunberger, Taylor L., Nartker, Nathan T., Nicholson, Cynthia L., Nahhas, Amanda F., Parks‐Miller, Angela, Hanna, Zachary, Jayaprakash, Rachna, Ramesh, Mayur S., Rambhatla, Pranita V., Hamzavi, Iltefat H.

“…Background A paucity of knowledge exists regarding the use of ertapenem in hidradenitis suppurativa. Our retrospective chart review and telephone interview…”
Get full text

A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19 by Zervos, Marcus, Arshad, Samia, Kilgore, Paul, Chaudhry, Zohra S., Jacobsen, Gordon, Wang, Dee Dee, Huitsing, Kylie, Brar, Indira, Alangaden, George J., Ramesh, Mayur S., McKinnon, John E., O’Neill, William

Get full text

Impact of time to treatment in first occurrence, non-severe Clostridioides difficile infection for elderly patients: are we waiting too long to treat? by Vandervelde, Rhett, Mlynarek, Mark E, Ramesh, Mayur, Patel, Nimish, Veve, Michael P, August, Benjamin A

“…Data evaluating timeliness of antibiotic therapy in infections (CDI) are not well established. The study's purpose was to evaluate the impact of time-to-CDI…”
Get full text

Impact of Early Corticosteroids on Preventing Clinical Deterioration in Non-critically Ill Patients Hospitalized with COVID-19: A Multi-hospital Cohort Study by Swaminathan, Lakshmi, Kaatz, Scott, Chubb, Heather, Tae, Kim, Ramesh, Mayur S., Fadel, Raef, Big, Cecilia, Jones, Jessica, Flanders, Scott A., Prescott, Hallie C.

“…Introduction While guidelines stronglyrecommend dexamethasone in critical COVID-19, the optimal threshold to initiate corticosteroids in non-critically ill…”
Get full text

Risk Factors for Surgical Site Infections Following Anterior Cruciate Ligament Reconstruction by Murphy, Michael V., Du, Dongyi (Tony), Hua, Wei, Cortez, Karoll J., Butler, Melissa G., Davis, Robert L., DeCoster, Thomas A., Johnson, Laura, Li, Lingling, Nakasato, Cynthia, Nordin, James D., Ramesh, Mayur, Schum, Michael, Von Worley, Ann, Zinderman, Craig, Platt, Richard, Klompas, Michael

“…OBJECTIVE To determine the effect of graft choice (allograft, bone-patellar tendon-bone autograft, or hamstring autograft) on deep tissue infections following…”
Get full text

Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI by Kraft, Colleen S., Sims, Matthew, Silverman, Michael, Louie, Thomas J., Feuerstadt, Paul, Huang, Edward S., Khanna, Sahil, Berenson, Charles S., Wang, Elaine E. L., Cohen, Stuart H., Korman, Louis, Lee, Christine, Kelly, Colleen R., Odio, Alberto, Cook, Paul P., Lashner, Bret, Ramesh, Mayur, Kumar, Princy, De, Ananya, Memisoglu, Asli, Lombardi, David A., Hasson, Brooke R., McGovern, Barbara H., von Moltke, Lisa, Pardi, Darrell S.

“…Introduction Recurrent Clostridioides difficile infection (rCDI) often occurs after standard-of-care antibiotics. VOWST oral spores (VOS, previously SER-109),…”
Get full text